News Release

Printer Friendly Version View printer-friendly version
<< Back
Aralez Appoints James L. Hall As General Manager Of Canadian Business

MILTON, Ontario, April 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that James L. Hall will be appointed to General Manager of its wholly owned subsidiary, Tribute Pharmaceuticals Canada Inc., effective May 16, 2016.

"We are pleased to have Jim assume the newly created position of General Manager, Canada," said Adrian Adams, Chief Executive Officer of Aralez. "His valuable commercial experience and track record having worked at a variety of impressive pharmaceutical companies will play a crucial role as we execute our global strategy and take the steps to advance our next phase of growth. I have tremendous respect for Rob Harris, who will remain on the Board of Aralez, and would like to thank him for what he and the entire Tribute team have built thus far."

Mr. Hall has more than 20 years of experience in sales, marketing, market access, operations and product development. He also has in-depth experience and a strong track record of success in both product promotion and launches. Prior to joining Aralez, Mr. Hall acted as Vice President of Commercial at Astellas Pharma with responsibility for sales, marketing, patient access and government relations, operations and new product planning. During his tenure, Mr. Hall successfully launched Myrbetriq® and Xtandi® while exceeding revenue and operating income targets. Previously, Mr. Hall held various senior level Commercial roles at Hoffmann La Roche, AstraZeneca, and Searle/ Pharmacia. Mr. Hall received his Bachelor of Engineering Science degree from the University of Western Ontario and Masters of Business Administration from McMaster University.

About Aralez Pharmaceuticals Inc. 
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at

Cautionary Language Concerning Forward-Looking Statements  
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to Aralez's global strategy and steps to advance its next phase of growth, and other statements that are not historical facts.  These forward-looking statements are based on Aralez's current assumptions and expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in each company's respective filings and reports with the SEC and SEDAR. The parties undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in their expectations.

Contact Information:

Aralez Pharmaceuticals US Inc.  
Nichol Ochsner 
Executive Director,  
Investor Relations & Corporate Communications 


To view the original version on PR Newswire, visit:

SOURCE Aralez Pharmaceuticals Inc.

Data provided by Nasdaq. Minimum 15 minutes delayed.